Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2022 call → NOWe need to answer YES or NO based on the provided transcript. The question asks whether management describes that their counterparts (customers, partners) are already losing something real and ongoing for as long as they do not have what the company provides, and that this accumulating loss is visible in how those parties are behaving toward the company today. Also, management should convey that this dynamic is generating business meaningful relative to company's size and contribution still ahead. We need to examine the transcript for any such description. Let's scan for relevant phrases. Key products: EYLEA, aflibercept 8mg, Dupixent, Libtayo, oncology pipeline, COVID antibody. Look for descriptions of counterparty losses or urgency. For example, in ophthalmology, they talk about EYLEA and competition. They mention that EYLEA is standard of care, and they are preparing for aflibercept 8mg launch. They talk about patient preference for fewer injections, but not necessarily about counterparts losing money or time. For Dupixent, they talk about launches and uptake, but no mention of counterparts accumulating losses. For oncology, they talk about unmet need and patients, but not about counterparts losing something. The transcript focuses on company progress, pipeline, financials. There is no description of customers or partners currently accumulating losses due to lack of product. The closest might be in COPD, where they talk about selecting patients with eosinophils, but no mention of counterparts losing. For COVID antibody, they talk about protecting vulnerable patients, but not about counterparts losing. The question is specific: management must describe ONE coherent situation with both halves: (1) running meter on the other side, (2) other side acting like meter is running. We need to find such a description in the transcript. Let's read carefully. In the prepared remarks, Leonard talks about strong performance, pipeline progress. No such description. Marion talks about EYLEA, mentions "short-term shift earlier in the quarter where EYLEA was negatively impacted by a temporary increase in use of off-label compounded Avastin" due to closure of co-pay fund. That's about company's loss, not counterparty. They talk about "competitive pressures" but not running meter. George talks about pipeline, but not about counterparty losses. Bob talks about financials.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...